Treace Medical Concepts Inc. (TMCI)
TMCI trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1630627/000119312526079167/0001193125-26-079167-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TMCI on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001630627 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | FL |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $212.7M |
| Net income | -$59.0M |
| Operating income | -$54.2M |
| Net margin | -27.7% |
| Operating margin | -25.5% |
| Revenue growth | +1.6% |
| Cash | $10.7M |
| Total assets | $190.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $7.8M cash; operating cash flow -$2.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 65,559,597 (2026-10-30); 63,718,073 a year earlier; 61,675,861 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Jacksonville, Florida, United States | PCAOB Form AP 2026-03-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $48.3M | -$12.6M | -$3.3M | $7.8M | $60.0M | $203.3M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $45.4M | -$15.9M | -$4.7M | $12.6M | $59.2M | $205.3M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $47.2M | -$18.0M | $7.2M | $9.5M | $57.6M | $207.3M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $62.5M | -$9.4M | -$8.0M | $10.7M | $57.3M | $212.7M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $50.2M | -$16.3M | -$9.1M | $7.7M | $55.3M | $218.9M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $47.4M | -$17.4M | -$3.0M | $8.1M | $54.6M | $213.8M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $52.6M | -$15.9M | $4.2M | $13.4M | $53.4M | $210.8M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $68.7M | -$501K | -$4.2M | $11.3M | $53.3M | $209.4M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-02-09 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 447 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +30.8% |
| 1 month | +28.5% |
| 3 months | +16.9% |
| Year to date | +115.1% |
| 1 year | +67.8% |
| From 52-week high | -1.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INFU | InfuSystems Holdings Inc. | $14.79 | +0.48% | $296.3M |
| OFIX | Orthofix Medical Inc. Common Stock (DE) | $6.80 | -5.16% | $277.2M |
| NPCE | Neuropace Inc. | $7.97 | +5.42% | $274.6M |
| SSII | SS Innovations International Inc. | $1.35 | -18.67% | $270.7M |
| PROF | Profound Medical Corp. | $7.34 | -1.08% | $268.8M |
| CLPT | ClearPoint Neuro Inc. | $8.30 | -2.12% | $266.1M |
| OSUR | OraSure Technologies Inc. | $3.60 | -0.55% | $248.6M |
| EMBC | Embecta Corp. | $6.25 | -3.25% | $354.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier